Selenium and Selenoproteins in Cancer

Edited by:   Francesco Galli (Clinical Biochemistry and Human Nutrition Department of Pharmaceutical Sciences University of Perugia)
Volume editor:   Kenneth D. Tew (Professor and Chairman Department of Cell and Molecular Pharmacology John C. West Chair of Cancer Research Medical University of South Carolina USA), Kenneth D. Tew (Department of Cell and Molecular Pharmacology, Medical University of South Carolina, USA), Kenneth D. Tew (Department of Cell and Molecular Pharmacology, Medical University of South Carolina, USA), Kenneth D. Tew (Department of Cell and Molecular Pharmacology, Medical University of South Carolina, USA)
Imprint:   Academic Press Inc
Country of Publication:   United States
Dimensions:   Height: 229mm,  Width: 152mm, 
Weight:   630g
ISBN:   9780128120163
ISBN 10:   0128120169
Series:   Advances in Cancer Research
Pages:   316
Publication Date:   19 October 2017
Audience:   Professional and scholarly ,  Undergraduate
Format:   Hardback
Publisher's Status:   Active

As the group leader and head of the research unit in the Department of Internal Medicine since 2013 and currently Dept of Pharmaceutical Sciences at University of Perugia, Francesco Galli's research is focussed on biochemistry, cellular biology and signaling, pharmacology/toxicology, and nutrition. Professor & Chairman, Dept of Cell & Molecular Pharmacology John C. West Chair of Cancer Research, Medical University of South Carolina, USAThe Tew laboratory maintains an interest in using redox pathways as a platform to develop therapeutic strategies through drug discovery/development and biomarker identification. We interrogate how reactive oxygen and nitrogen species (ROS/RNS) impact cancer cells and develop novel drugs that impact on glutathione based pathways. Our research efforts have been integral to studies that have identified glutathione S-transferases (GST) as important in drug resistance, catalytic detoxification and as arbiters of kinase-mediated cell signaling events. In addition, we have been instrumental in defining how GSTP contributes to the process by which cells respond to ROS by selective addition of glutathione to specific protein clusters, so called S-glutathionylation. Each of these research areas has had broad impact on a number of cancer disciplines. Moreover, we have also been seminally involved in the Phase I to III clinical testing of three oncology drugs, Telcyta, Telintra and NOV-002. Other ongoing translational efforts have produced two ongoing clinical trials to measure the effectiveness of serum S-glutathionylated serine proteinase inhibitors as possible biomarkers for exposure to hydrogen peroxide mouthwashes and radiation.